Nikolaos Trikalinos is an Oncology physician affiliated with Washington University in St. Louis. OpenAlex indexes 192 publications with 2,022 citations (h-index 16); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Div Im Medical Oncology, Ste 7a, 7b, 7c
Saint Louis, MO 631101032
Telephone
800-647-2098Registry record last updated 17 Apr 2025.
Clinical trials
- Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Sponsor: Washington University School of Medicine
- Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)
Sponsor: Washington University School of Medicine
- ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year20251 payment
- Ipsen Biopharmaceuticals, IncProgram year20221 payment
- Acrotech Biopharma LLCProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
62.7%PD-1 inhibitor45%Pembrolizumab100%Part B, office-administered≥11 patientsCD38-directed Cytolytic Antibody17.7%Daratumumab100%Part B, office-administered≥13 patientsMetabolism & gastrointestinal
20.1%Other antiemetics14.7%Fosaprepitant100%Part B, office-administered≥11 patientsSerotonin-3 Receptor Antagonist4.9%Palonosetron hcl69%Granisetron hydrochloride27%Ondansetron Hcl4%Part D + Part B≥25 patients+ 4 more classes in this area
Hormonal (systemic)
10.4%Somatostatin Analog10.4%Octreotide100%Part B, office-administered≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
New England Journal of Medicine
2024 - A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i> <i>-</i> Altered Advanced Solid Tumor Malignancies (NCI 10170)
Cancer Research Communications
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Ley, MD
Washington University in St. Louis
David Gutmann, MD
Washington University in St. Louis
Randall Bateman, MD
Washington University in St. Louis
Victoria Fraser, MD
Washington University in St. Louis
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”